Thengchaisri Naris, Miriel Victor A, Rivers Richard J
Johns Hopkins University, Department Anesthesiology and Critical Care Medicine, 720 Rutland Ave., Baltimore, MD 21205, USA.
Microvasc Res. 2009 May;77(3):356-63. doi: 10.1016/j.mvr.2009.01.004. Epub 2009 Jan 27.
We previously demonstrated a vascular network response initiated by elevated tissue concentrations of adenosine that is distinct from the dilation caused when adenosine is applied directly to the arteriole. The purpose of this study was to elucidate the potential mechanism(s) for the different responses. In the cheek pouch of anesthetized hamster, arteriolar responses were measured when adenosine (10(-4)M) was applied with micropipette into the tissue 500 microm from the arteriole (n=67, baseline diameter 22+/-0.6 microm) or onto the arteriole itself. Application of adenosine to the vessel or into the tissue caused arteriolar dilation with similar concentration profiles. In stark contrast, the concentration profiles were significantly different for vessel and tissue initiated dilation when either sodium nitroprusside or methacholine was tested. Arteriolar dilation was not enhanced when adenosine was simultaneously applied with two pipettes at along a single arteriole; however, the dilation doubled when adenosine was applied simultaneously at arteriole and tissue. Control dilations caused by tissue adenosine (5+/-0.4 microm) were not altered by superfusion of the A(1) receptor antagonist DPCPX (10(-6)M; 4.6+/-0.3 microm), A(2B) receptor antagonist alloxazine (10(-6)M; 6+/-0.8 microm), or A(3) receptor antagonist MRS1220 (5 x 10(-9)M; 6+/-0.8 microm) but were abolished by the selective A(2A) receptor antagonist ZM241385 (10(-7)M; 1+/-0.2 microm), suggesting that activation of A(2A) receptors mediates these network responses. Disruption of arteriolar endothelium and direct arteriolar application of ZM241385 (10(-7)M; 5+/-0.4 microm) did not alter the dilation caused by tissue adenosine. However, local application of ZM241385 into the tissue inhibited adenosine-induced network responses (2+/-0.3 microm). Furthermore, application into the tissue of A(2A) receptor agonist CGS21680 (10(-5)M), but not A(1) (CPA; 10(-4)M), A2b (NECA, 10(-4)M) or A3 (IB-MECA; 10(-4)M) receptor agonists mimicked the adenosine network response. These data demonstrate dual, complimentary, yet distinct pathways for network dilations induced by increases in tissue adenosine.
我们之前证明了由组织中腺苷浓度升高引发的血管网络反应,这与直接将腺苷应用于小动脉时引起的扩张不同。本研究的目的是阐明不同反应的潜在机制。在麻醉的仓鼠颊囊中,当用微量移液器将腺苷(10⁻⁴M)应用于距小动脉500微米的组织中(n = 67,基线直径22±0.6微米)或直接应用于小动脉本身时,测量小动脉反应。将腺苷应用于血管或组织中会导致小动脉扩张,其浓度曲线相似。然而,当测试硝普钠或乙酰甲胆碱时,血管和组织引发的扩张的浓度曲线存在显著差异。当沿着单个小动脉用两个移液器同时应用腺苷时,小动脉扩张并未增强;然而,当在小动脉和组织同时应用腺苷时,扩张增加了一倍。由组织腺苷引起的对照扩张(5±0.4微米)不受A₁受体拮抗剂DPCPX(10⁻⁶M;4.6±0.3微米)、A₂B受体拮抗剂咯嗪(10⁻⁶M;6±0.8微米)或A₃受体拮抗剂MRS1220(5×10⁻⁹M;6±0.8微米)的灌注影响,但被选择性A₂A受体拮抗剂ZM241385(10⁻⁷M;1±0.2微米)消除,这表明A₂A受体的激活介导了这些网络反应。小动脉内皮的破坏以及ZM241385(10⁻⁷M;5±0.4微米)直接应用于小动脉并未改变由组织腺苷引起的扩张。然而,将ZM241385局部应用于组织中会抑制腺苷诱导的网络反应(2±0.3微米)。此外,将A₂A受体激动剂CGS21680(10⁻⁵M)应用于组织中可模拟腺苷网络反应,而A₁(CPA;10⁻⁴M)、A₂B(NECA,10⁻⁴M)或A₃(IB - MECA;10⁻⁴M)受体激动剂则不能。这些数据证明了由组织腺苷增加诱导的网络扩张存在双重、互补但又不同的途径。